In MiMARK, we care for women's health. We are specialized in the discovery, verification and validation of biomarkers to develop new solutions for gynecological patients.
Abnormal uterine bleeding affects 14M between women in EU and US yearly (in women between 50 and 75 years old). Diagnosis of endometrial cancer is mandatory for all those women as 10% of those will be diagnosed with the disease. Current diagnosis is based on the pathological examination of an endometrial biopsy (pipelle biopsy), but this fails to diagnose in up to 30% of patients, and provides an inaccurate diagnosis in up to 55% of cases. This failure is associated to the scarce cellularity of the sample. In those cases, invasive diagnosis using histeroscopy needs to be performed.
Our solution: WomEC. It is an in vitro diagnostic tool based on the determination of 5 protein biomarkers in uterine fluid samples to provide diagnosis to 100% of patients, rule out endometrial cancer with great specificity, and provide information on histological subtype of the tumor to guide surgical treatment.
Company Details
- Employees
- 27
- Founded
- -
- Address
- Avinguda Dr. Gregorio Marañón 8, Barcelona,barcelona 08028,spain
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- https://www.mimark.es/
- Keywords
- IT Consulting.
- HQ
- Barcelona, Barcelona
Mimark Diagnostics Questions
Mimark Diagnostics's website is https://www.mimark.es/
Mimark Diagnostics's LinkedIn profile is https://es.linkedin.com/company/mimarkdx
Mimark Diagnostics has
27 employees.
View email and phone details for 27
employees at Mimark Diagnostics.
Mimark Diagnostics's industry is
Biotechnology Research
Mimark Diagnostics's top competitors are
Deepull,
Nuage Therapeutics,
Genomcore,
Minoryx Therapeutics,
Methinks Ai,
Splicebio,
Ona Therapeutics,
Seqera,
Aptadel Therapeutics,
Onechain Immunotherapeutics.
Mimark Diagnostics's categories are Biotechnology Research
Mimark Diagnostics's founding year is 2021
